Burden of Atopic Dermatitis

The chronic, persistent nature of atopic dermatitis (AD) means it’s always there, even when patients may appear asymptomatic.1

AD Burden: Debilitating and More Severe When Uncontrolled

  • Patients with moderate-to-severe AD report potentially debilitating signs and symptoms such as excessive itch, dryness, scaling, and open sores—all of which can lead to pain, sleep disturbance, and impaired social functioning2-4
  • Inadequately controlled patients had a greater physician-reported AD burden than those with controlled AD5

Inadequate Disease Control Increases
With the Severity of AD5

2014 Adelphi US Disease-Specific Program: a cross-sectional survey of physicians (n=202) and their patients (n=1064); >18 years5
File: graph-patients-inadequate-atopic-dermatitis-control alt text: graph created by LEO Pharma showing correlation of inadequate ad control and physician-rated severity; Adapted from Wei W et al.

Adapted from Wei W et al.5

Inadequate Disease Control Increases the Burden of AD5

2014 Adelphi US Disease-Specific Program: a cross-sectional survey of physicians (n=202) and their patients (n=1064); >18 years5
graph created by LEO Pharma comparing inadequately controlled vs controlled atopic dermatitis. The graph highlights the impact of inadequately controlled AD on depression, stress, itch, and sleep disturbance. Adapted from Wei W et al.

Adapted from Wei W et al.5

Understanding the difficulties that patients face is just one part of tackling this debilitating disease. Atopic dermatitis has a complex pathophysiology that drives the visible signs, symptoms, and underlying inflammation.6-9

Discover the pathophysiology of AD

  1. Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Non-lesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964.e1-4.
  2. Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327-334.
  3. Avena-Woods C. Overview of atopic dermatitis Am J Manag Care. 2017;23(8):S115-S123
  4. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association J Investig Derm. 2017;137(1):26-30
  5. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150-157.
  6. Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol. 2007;127(1):129-134.
  7. May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015;75(1):89-116.
  8. Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(65):1-10.
  9. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387(10023): 1109–22